In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

In a patient with generalized MG, for whom symptoms started at age 50–65 years, with an enlarged thymus on imaging, and antibodies against AChR only, thymectomy should be recommended.

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

Like Soliris and Ultomiris, Zilbrysq is approved for use in adults with gMG who are anti-acetylcholine receptor (AChR) antibody ... chief executive of the Myasthenia Gravis Foundation of America.

for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study.

a treatment for generalized myasthenia gravis (gMG) in antibody-positive patients, including those with anti-AChR, anti-MuSK, and anti-LRP4 antibodies. The Priority Review designation applies to ...

Approval in Myasthenia gravis in key markets could eventually ... open-label study which found benefits for patients with anti-AchR antibody-positive gMG who had previously failed ...

Myasthenia gravis occurs when the immune system has an abnormal response and produces a type of harmful antibody. These antibodies target and attack receptors called anti-AChR receptors in the ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Myasthenia gravis (MG) is an autoantibody disease in which the immune system mistakenly makes antibodies (e.g., anti-acetylcholine receptor [AChR], anti-muscle-specific tyrosine kinase [MuSK] or ...